Introduction
The efficacy of anticoagulation for primary prevention of stroke or transient ischemic attacks (TIA) in patients with nonvalvular atrial fibrillation (NVAF)has been established by five prospective, randomized and controlled trials (1) (2) (3) (4) (5) . Thus, warfarin treatment using international normalized ratios (INR) ranging from 2.0 to 3.0 (or 4.0) is recommended for NVAF patients, who have any of the following risk factors; history of previous stroke or TIA, diabetes mellitus, hypertension, advanced age (>75 years old), congestive heart failure, and coronary artery disease (6) (7) (8) .
The efficacy of warfarin treatment for secondary prevention of stroke in NVAFpatients has been evaluated by three prospective studies, European Atrial Fibrillation Trial (EAFT), Stroke Prevention in Atrial Fibrillation III randomized clinical trial (SPAFIII) and Japanese Nonvalvular Atrial FibrillationEmbolism Secondary Prevention Cooperative Study (9-1 1). The EAFTstudy reported that warfarin treatment with INR ranging from 2.5 to 4.0 was effective for secondary prevention, because of the risk reduction of ischemic stroke from 12% to 4%per year and a low incidence of major hemorrhagic events (2.8%/year) (9) . All hemorrhagic complications, however, were observed more frequently in the anticoagulation group than in the control group (hazard ratio 3.4, 95% CI 1.9-6.0, p<0.001). Although the risk of stroke is high in NVAFpatients with a history of stroke, the INR range used in the European study seems inappropriately high when compared both to the recom-mended INR range for primary prevention and to the ordinary INR level applied to elderly patients. The study indicated that no treatment effect was apparent with anticoagulation below an INR of 2.0 (12). However, the conclusion was obtained by comparing the event rate in a group of patients with INR between 1.0 and 1.9 with those in other groups of patients with INR above 2.0. The efficacy was not assessed by further dividing the group ofINR between 1.0 and 1.9. A major hemorrhage often develops in elderly patients on anticoagulation therapy while the lowest intensity to effectively prevent ischemic stroke has not been clearly determined. Accordingly, anticoagulation with warfarin is controversial for the treatment of elderly patients with NVAF. Recently, a multicenter, prospective, randomized study from Japan demonstrated that the low intensity warfarin treatment (INR 1.5 to 2. 1) for prevention of stroke recurrence was safer than the conventional intensity treatment (INR 2.2 to 3.5) in the elderly (ll). However, because recurrent stroke wasseen in only one out of 46 patients aged 70 or more in the study, the lowest intensity of warfarin treatment in the elderly to prevent ischemic stroke is still unknown. Stroke prevention in atrial fibrillation III (SPAF III) study demonstrated that very low intensity warfarin treatment (INR 1.2-1.5) was not useful to prevent recurrent stroke in NVAF compared to conventional warfarin therapy (INR 2.0-3.0) ( 10, 13) . This study indicated partial efficacy of warfarin control with INR between 1.6 and 1.9. Wefound by a retrospective study that anticoagulant therapy with INR >1.6 effectively prevented a large infarct and poor outcome, even whenischemic stroke did occur in patients with an emboligenic heart disease (14) . To determine optimal intensity of INR for secondary prevention of major ischemic and hemorrhagic events, weprospectively conducted National Cardiovascular Center (NCVC) NVAFSecondary Prevention Study and analyzed data with those of Japanese Nonvalvular Atrial Fibrillation-embolism Secondary Prevention Cooperative Study ( 1 1).
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Methods
Werecruited NVAF patients at the outpatient clinic of the Cerebrovascular Division of NCVCin July and August of 1998, whohad a history of ischemic stroke or TIA more than one month prior to the enrollment, and were undergoing anticoagulant therapy for secondary prevention (NCVCNVAFSecondary Prevention Study). After a written informed consent was obtained from patients or their family, patients were enrolled in the study. Weobtained patients' clinical history in terms of hypertension, diabetes mellitus, continuous or paroxysmal atrial fibrillation, angina pectoris, myocardial infarction, and number of past episodes of stroke. Hypertension was defined as the use of antihypertensive agents or blood pressure recordings with systolic >160 mmHg or diastolic >95 mmHg. Diabetes mellitus was defined as use of insulin or oral hypoglycemic agents, fasting blood glucose levels >140 mg/dl, or random blood glucose levels >200 mg/ dl.
The enrolled patients were evaluated for two years for ischemic and major hemorrhagic events by expert stroke physicians once a month with monitoring INR. Ischemic events included brain infarction, TIA, and embolism to other parts of the body. Weregarded ischemic stroke with NIHstroke scale (NIHSS) score >10 or systemic embolism as major ischemic events and ischemic stroke with NIHSSscore <10 as minor ischemic events. Meanvalues of INR before and just after the events were counted as an INRassociated with the events. We regarded the meanINRvalue of two continuous sampling points as a representative INR during the period between the two sampling points. Then, we calculated the incidence rate (per 100 person years) of ischemic and hemorrhagic events by INR <1.59, 1.60-1.99, 2.00-2.59 and >2.60.
Major hemorrhagic complications were brain hemorrhage, retinal hemorrhage, or other severe hemorrhagiccomplications that were fatal or required hospital admission for emergency treatment or blood transfusion. Patients were followed for 24 months, or until any ischemic or major hemorrhagic events occurred. The target intensity of INR was decided by the physician in charge. Modified-Rankin scale score was obtained at entry and 3 months after the endpoint event (15) . At the time of admission due to endpoint of brain infarction or brain hemorrhage, the NIHSSscore was evaluated (16) . The Japanese NVAF-Embolism Secondary Prevention Cooperative Study was conducted between April 1994 and March 1998 in 19 institutions in Japan (ll). They recruited 115 patients aged 66.7+6.5 year and randomly allocated 55 patients to a conventional intensity group (target INR 2.2 to 3.5) and 60 to low intensity group (target INR 1.5 to 2.1). The trial was stopped after a follow-up of 658±423 days, when major hemorrhagic complication occurred in 6 patients of the conventional intensity group and the frequency (6.6%/year) was significantly higher than that in the low intensity group (0%/year, p=0.01 , Fisher's exact test). Because they did not evaluate score of NIHSSat onset of stroke, we regarded stroke with socially independent or independent at homeas minor stroke and dependentat homeor worseas majorstroke. Table 1 . During the study period of two years, there were 14 patients whodeveloped ischemic or major hemorrhagic events and three patients dropped out. The mean follow-up period was 646±219 days ( Table 2 ). The ischemic events were seen in 1 1 patients, four were major ischemic events and the other seven were minor ischemic events ( 
41, and 2.66). Out of the four patients with major ischemic events, three had major strokes (NIHSS at admission >10) and one suffered a fatal embolism to the mesenteric artery. Their modified Rankin scale scores at entry deteriorated at 3 months after the endpoints from 0 to 4, 0 to 3, 1 to 4, and 2 to dead, respectively. In the seven patients with minor ischemic events, the modified Rankinscale scores at entry were 0 in three of them and 1 in three and 2 in the other one. Their scores did not change 3 months after the endpoints in six patients, but the score increased from 1 to 2 in the remaining one. There were three patients who developed major hemorrhagic complications, brain hemorrhage in two and subdural hematoma with INR of 2.44, 2.94 and 3. 18, respectively. Their modified Rankin scale scores at entry were 1, 1, and 2 and those at 3 months after the endpoint were 4, 1 , and 4, respectively. Minor bleeding was seen in sixteen patients. Whenwe combined the two studies, the current study (NCVCNVAFSecondary Prevention Study) and the previous The SPAFIII study demonstrated that the annual event rate of ischemic stroke or systemic embolism in a group of patients with INR between 1.5 and 1.9 was lower than those in groups of patients with INR below 1.5 (10) . Two randomized prospective studies on the primary prevention of stroke in NVAF patients using 1.4 and 1.5 as the lower limits of target INR, demonstrated the usefulness of anticoagulant therapy with warfarin (2, 5) . Although the option of a lower intensity anticoagulation in the elderly than recommendedin the younger has been suggested ( 1 8), the effect of lower intensity of anticoagulation on severity of ischemic events has not been elucidated yet. According to the present study, the lower limit of the intensity of anticoagulation for secondary prevention of severe ischemic events appeared to be approximately 1.6 (Fig. 2) . This result was in good agreement with the INR value that had been obtained by the retrospective study comparing INR and the size of brain infarct (14) . Anticoagulation with INR between 1.6 and 1.9 may have not only partial efficacy in reducing stroke occurrence (13) , but it may also have an effect to prevent major ischemic events. Minor stroke occurred in not only patients with INR<1.6 but also in those with INR >1.6. The failure to prevent minor stroke in patients with INR above 1.6 may be related to the mechanism of stroke recurrence. Although it is well known that cardioembolic stroke is prone to recur (19, 20) , some minor strokes fromthe other causes, such as atherothrombotic or lacunar infarction, may occur even in patients with higher INR. Such strokes are usually less severe and do not respond as well to anticoagulant prevention as cardioembolic stroke. It has already been reported that the size of intracardiac thrombus was reduced by anticoagulation, which*wasattributed to the relative predominance of plasma fibrinolytic activity over thrombin activity by anticoagulation (2 1). Therefore, even when a thrombus is formed in patients with INR>1.6, it will probably be small, and even when they develop ischemic stroke, it may result in small brain infarct.
The results of analyzing combined data demonstrated a sharp arise in the incidence of severe hemorrhage in INR >2.6 and most patients suffering severe hemorrhagewere elderly. Therefore it is recommendedto avoid INR>2.6 in treating the elderly. This value was consistent with previous suggestions (18) . Although patients were randomly assigned into two groups receiving low or conventional intensity of INR in the Japanese NVAF-Embolism Secondary Prevention Cooperative Study, the level of INR in each patient was determined by the physician in charge in the NCVC-NVAF Secondary Prevention Study. Therefore, the decision of INRlevel in the latter study may have been affected by bias. It seems that a prospective randomized study is required in a large number of elderly NVAF patients in order to elucidate whether the INRrange between 1.6 and 2.6 is more useful than the conventional range of INR between 2.0 and 3.0 in the prevention of stroke in the elderly NVAFpatients.
